Treating ALS in a Dish? Models Point to Drug Candidate for Sporadic Disease
The dopamine receptor agonist ropinirole emerged as the top hit in a screen of induced motor neurons.
ALL NEWS
6538 RESULTS
Sort By:
- Most Recent
- Most Commented
For the Faint of Heart: Doc, Want to Check Their NfL?
What's the use of measuring neurofilament light in blood? The marker could help with AD trial enrollment and measuring drug effects. It could even guide brain-sparing improvements in heart surgery, say researchers at AAIC 18.
Cognitive Deficits Worse with ALS Stage
Neuropsychological impairments are common in amyotrophic lateral sclerosis, even more so for people at late stages of disease.
RNA-Binding Protein Linked to Ataxin-2 toxicity
Staufen1 may deplete certain mRNAs, precipitating the death of Purkinje and other neurons.
$2.34 Billion Alzheimer’s Budget Signed Into Law
The bill tops last year’s budget for the disease by $425 million.
In Mice, Caspase-1 Inhibitor Quells Inflammation, Aβ, Memory Loss
VX-765 could be a therapeutic candidate for Alzheimer’s disease.
ALS on a Chip—A Model for Screening Therapeutics?
Neuromuscular junctions between human stem cell-derived motor neurons and skeletal muscle fibers faltered when cells came from an ALS patient.
High-Resolution Map of Hippocampus Reveals Multiple Subnetworks
The most detailed look yet at hippocampal wiring may guide future functional studies and disease research.
Getting Between Fibrin and Complement Receptor Cools Inflammation
An antibody that binds fibrin blocks neuro-inflammatory signaling while allowing normal clotting.
African-American Participation in AD Research: Effective Strategies
Alzheimer’s Researchers Seek Advice on How to Include African-Americans Do African-Americans Have More, or Different, Alzheimer’s Disease? Too Little Data to Tell Is Alzheimer’s more common, or different, in black Americans? Or do cerebrovascular risk fac
Alzheimer’s Researchers Seek Advice on How to Include African-Americans
Despite having a higher incidence of Alzheimer’s or a related dementia, relatively few black people participate in research studies or drug trials. How to achieve full representation?
Do African-Americans Have More, or Different, Alzheimer’s Disease? Too Little Data to Tell
At a workshop on engaging more black Americans in ADRD research, new CSF findings stood out against a general dearth of data on Alzheimer’s disease in underrepresented minorities.
Second Look at BAN2401 Data Still Positive, Despite Snafu
Subgroup analysis addresses APOE4 randomization imbalance, claims treatment with this anti-Aβ protofibril antibody slowed cognitive decline.
Clinical Trials on Alzheimer's Disease 2018
Bump in the Road or Disaster? BACE Inhibitors Worsen Cognition Second Look at BAN2401 Data Still Positive, Despite Snafu Blood Tests for Amyloid Step Out at CTAD It’s Official: Tau PET Sees Tangles, and Staging Tangles Predicts Decline Amyloid PET Aids Di
More Private Funding for Alzheimer’s Research
New awards plow $5 million into synthesizing published AD data and $6 million into early stage clinical trials.
Current Filters
No filters selected